TerminatedNot Applicable

Evaluation of Pharmacist-led Medication Reconciliation Service Benefits in Hospitalised Medical Patients

Stopped: Due to COVID 19 declaration in Slovenia for the second time and subsequent reorganization of intervention ward

Slovenia553 participantsStarted 2019-09-30

Plain-language summary

Background: Transitions of care often lead to medication errors and unnecessary healthcare utilisation. It has been repeatedly shown that medication reconciliation can at least partially reduce this risk. Objective: The aim of this prospective pragmatic trial was to evaluate the effectiveness of pharmacist-led medication reconciliation offered to medical patients as part of routine clinical practise. The main questions to be answered were: * the effectiveness of pharmacist-led medication reconciliation on medication discrepancies at discharge and 30 days after discharge * the effectiveness of pharmacist-led medication reconciliation on healthcare utilisation within 30 days after discharge. Participants in the intervention group were offered the following: * medication reconciliation on admission * medication reconciliation on discharge, coupled with patient counselling, provided by clinical pharmacists. Participants in the control group were offered standard care.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All adult medical patients admitted to the study wards Exclusion Criteria: * patients who do not speak Slovenian, * transferred from another ward, * previously included in the same study. Subsequent exclusion from the analysis: * patients hospitalised only for diagnostic purposes, * patients transferred to another ward or hospital, * patients that died during hospitalisation, * patients from the control group who were offered medication reconciliation

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Unplanned healthcare utilisation within 30 days after discharge

Timeframe: within 30 (±5) days after hospital discharge

Trial details

NCT IDNCT06207500

SponsorThe University Clinic of Pulmonary and Allergic Diseases Golnik

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-10-18

View on ClinicalTrials.gov More Medication Reconciliation trials